WOCKPHARMA

Submits NDA for Zaynich, Targeting US Launch in FY27

Drugmaker

has submitted a New Drug Application (NDA) to the USFDA for its novel antibiotic, Zaynich, marking a significant milestone for Indian pharmaceutical innovation. → Zaynich is designed to treat complicated Urinary Tract Infections (cUTIs) caused by multi-drug resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria, including Pseudomonas Aeruginosa and carbapenem-resistant strains. → In Phase III clinical trials, Zaynich demonstrated a superior efficacy profile, achieving a 96.8% cure rate in cUTI and 89% overall efficacy, outperforming the standard-of-care drug, Meropenem, by 20%. The novel antibiotic has already been used on a compassionate basis, reportedly saving at least 51 lives in the US and India as of mid-2025. → Zaynich has been granted Fast Track and Qualified Infectious Disease Product (QIDP) designations by the USFDA, which expedites the review process and provides an incentive of five additional years of market exclusivity upon approval. → Wockhardt is targeting an NDA decision by mid to late 2026 and aims for a US launch in FY27. If approved, Zaynich would tap into a global market for Gram-negative infections valued at over $7 billion and has the potential to become a blockbuster drug, given the annual cUTI caseload of over 8 million in the US and EU. → The company is prioritizing the self-commercialization of the drug in the US, while remaining open to partnership opportunities. → Zaynich is the first Indian-discovered antibiotic to reach the NDA stage with the USFDA, a success that could pivot India’s pharma reputation from a generics powerhouse to an innovative drug discovery hub. → This R&D focus is significant as major pharma companies had largely abandoned antibiotic research due to an unfavorable economic model (low price, short duration of use, and high development cost), a gap that the US GAIN Act incentives are now helping to fill.